Jensen, Simon Birk Kjær
Janus, Charlotte
Lundgren, Julie Rehné
Juhl, Christian Rimer
Sandsdal, Rasmus Michael http://orcid.org/0000-0003-0590-6285
Olsen, Lisa Møller
Andresen, Anne
Borg, Signe Amalie http://orcid.org/0000-0002-6455-178X
Jacobsen, Ida Christine http://orcid.org/0000-0003-0653-4364
Finlayson, Graham
Stallknecht, Bente Merete
Holst, Jens Juul http://orcid.org/0000-0001-6853-3805
Madsbad, Sten http://orcid.org/0000-0002-5017-1815
Torekov, Signe Sørensen http://orcid.org/0000-0001-6779-0252
Article History
Received: 5 January 2022
Accepted: 26 July 2022
First Online: 15 August 2022
Competing interests
: SM: <i>Advisory boards:</i> AstraZeneca; Boehringer Ingelheim; Eli Lilly; Merck Sharp & Dohme; Novo Nordisk; Sanofi Aventis. <i>Lecture fees:</i> AstraZeneca; Boehringer Ingelheim; Merck Sharp & Dohme; Novo Nordisk; Sanofi Aventis. <i>Research Grant Recipient</i>: Novo Nordisk, Boehringer-Ingelheim. JJH: Advisory boards: Novo Nordisk. SST: <i>Research Grant Recipient</i> Novo Nordisk. RMS: Family member holds Novo Nordisk stock. All other authors declare no competing interests.